Literature DB >> 6123884

Efficacy and tolerance of ivermectin in human onchocerciasis.

M A Aziz, S Diallo, I M Diop, M Lariviere, M Porta.   

Abstract

Initial clinical studies in 32 Senegalese subjects have demonstrated the efficacy of ivermectin in Onchocerca volvulus infection (river blindness). Although O. volvulus microfilariae in skin snips were not reduced in number after single oral doses of 5 micrograms or 10 micrograms/kg body-weight, they were greatly reduced in all subjects after single oral doses of 30 micrograms or 50 micrograms/kg and were eliminated completely in 6 of th 8 subjects who received the 50 micrograms/kg dose. All subjects tolerated the drug well. Transient pruritus which did not require treatment was observed on the day the dose was given in 2 of the 8 subjects after the 30 micrograms/kg dose and in 4 of the 8 who received the 50 micrograms/kg dose. Ivermectin produced no abnormal laboratory results.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6123884     DOI: 10.1016/s0140-6736(82)91026-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  40 in total

1.  Organization of the biosynthetic gene cluster for the polyketide anthelmintic macrolide avermectin in Streptomyces avermitilis.

Authors:  H Ikeda; T Nonomiya; M Usami; T Ohta; S Omura
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Avenolide, a Streptomyces hormone controlling antibiotic production in Streptomyces avermitilis.

Authors:  Shigeru Kitani; Kiyoko T Miyamoto; Satoshi Takamatsu; Elisa Herawati; Hiroyuki Iguchi; Kouhei Nishitomi; Miho Uchida; Tohru Nagamitsu; Satoshi Omura; Haruo Ikeda; Takuya Nihira
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

3.  Decrease in adverse reactions after repeated ivermectin treatment in onchocerciasis.

Authors:  A Van der Lelij; A Rothova; N Klaassen-Broekema; W R Wilson; R F Barbe; J S Stilma
Journal:  Doc Ophthalmol       Date:  1990-10       Impact factor: 2.379

4.  Phase III Clinical Trial to Evaluate Ivermectin in the Reduction of Mansonella ozzardi infection in the Brazilian Amazon.

Authors:  Sergio de Almeida Basano; Juliana de Souza Almeida Aranha Camargo; Gilberto Fontes; Antonieta Relvas Pereira; Jansen Fernandes Medeiros; Mayara Costa de Oliveira Laudisse; Ricardo de Godoi Mattos Ferreira; Luís Marcelo Aranha Camargo
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

5.  Modeling targeted ivermectin treatment for controlling river blindness.

Authors:  Eric M Poolman; Alison P Galvani
Journal:  Am J Trop Med Hyg       Date:  2006-11       Impact factor: 2.345

Review 6.  Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis.

Authors:  K L Goa; D McTavish; S P Clissold
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

7.  Effect of single-dose ivermectin therapy on human Onchocerca volvulus infection with onchocercal ocular involvement.

Authors:  H S Newland; A T White; B M Greene; S A D'Anna; E Keyvan-Larijani; M A Aziz; P N Williams; H R Taylor
Journal:  Br J Ophthalmol       Date:  1988-08       Impact factor: 4.638

8.  Principles of activation and permeation in an anion-selective Cys-loop receptor.

Authors:  Ryan E Hibbs; Eric Gouaux
Journal:  Nature       Date:  2011-05-15       Impact factor: 49.962

9.  Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection.

Authors:  P T Soboslay; C G Lüder; W H Hoffmann; I Michaelis; G Helling; C Heuschkel; C M Dreweck; C H Blanke; S Pritze; M Banla
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

Review 10.  Points of action in the campaign against blindness in developing countries.

Authors:  J S Stilma; S Franken; M Hogeweg; P Hardus
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.